Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose-ascending, Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ACP-001 (TransCon PEG hGH)

NCT01010425 is registered in ClinicalTrials.gov with Ascendis Pharma A/S as lead sponsor.

NCT NCT01010425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01010425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose-ascending, Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ACP-001 (TransCon PEG hGH)
Lead sponsor
Ascendis Pharma A/S
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2009
Completion date
May 31, 2010
Enrollment
44 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy